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DObjective: Extracorporeal life support (ECLS) is a widely accepted modality for the treatment of postoperative
low cardiac output syndrome (LCOS) after major cardiac surgery by providing temporary circulatory support for
the stunned myocardium. We sought to identify the factors that affect outcomes of ECLS for postoperative
LCOS.
Methods: From 2005 to 2011, of a total of 9267 adult patients underwent major cardiac surgery, 93 patients
(aged, 60.6  13.8 years; 47 women) underwent ECLS to treat postoperative LCOS.
Results: Thirty-nine (41.9%) patients were weaned off ECLS successfully, and 1 patient underwent heart trans-
plantation. A final total of 23 patients (24.3%), including 1 heart transplantation recipient, survived until the
end of the follow-up period (median, 611 days; range, 125-2247 days). On logistic regression analysis, old
age (P ¼ .001), a high blood lactate level before ECLS initiation (P<.001), cardiopulmonary bypass weaning
failure after surgery (P<.001), and postoperative bleeding (P¼ .012) were independent factors associated with
mortality. In contrast, administration of anticoagulant nafamostat mesilate (P¼ .040) was found to be associated
with improved outcomes of ECLS. When the predictive value of pre-ECLS blood lactate level for mortality was
assessed using the receiver operating characteristic curve, the greatest accuracy was obtained at the cutoff value
of 7.9 mmol/L, with 63% sensitivity and 68% specificity.
Conclusions:High lactate level before ECLS is an independent predictor of mortality after ECLS, necessitating
earlier ECLS implementations before profound lactic acidosis develops. Moreover, nafamostat mesilate should
be considered as alternative to heparin to reduce the risk of bleeding in these high-risk patients. (J Thorac
Cardiovasc Surg 2014;147:283-9)Extracorporeal life support (ECLS) is a widely accepted
modality for the treatment of postoperative low cardiac out-
put syndrome (LCOS) after major cardiac surgery.1-5 By
providing temporary circulatory support for the stunned
myocardium, ECLS allows time for cardiac recovery.6
When the failing heart is unlikely to recover despite pro-
longed ECLS for more than 48 to 72 hours, either implanta-
tion of a ventricular assist device (VAD) or heart
transplantation (HT) is desirable before the onset of end-
organ insults.2,7 Unfortunately, these destination therapies
for irreversible cardiac insults are still practically
unavailable in many developing countries because of their
cost and the limited availability of donor hearts. In South
Korea, for instance, the National Health Insurance
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number of donor hearts is very limited in Korea, bridging
to HT is rarely successful in cases of postoperative
irreversible heart failure.8 Consequently, the recovery of car-
diac function by the use of ECLS may be the only option for
management of postoperative LCOS after cardiac surgery in
many countries under similar conditions. In these regards,
there have been only a few reports related to the use of
ECLS as a ‘‘bridge-to-recovery’’ for LCOS after cardiac sur-
gery. Therefore, the present study aimed to evaluate the early
outcomes of ECLS after major cardiac surgery and to deter-
mine the predictive factors of mortality.PATIENTS AND METHODS
Patients
Between May 2005 and December 2011, 9267 adult patients underwent
major cardiac surgery at the AsanMedical Center, Seoul, Korea. These op-
erations included valve surgery, coronary artery bypass grafting, aortic sur-
gery, resectioning of cardiac tumors, pericardiectomy, pulmonary
thromboembolectomy, and HT. Among these patients, 103 (1.1%) required
postoperative ECLS for LCOS. The exclusion of 10 patients who received
ECLS preoperatively left a final cohort that comprised 93 patients and
formed the subject population in this study. The breakdown of patients
with different clinical situations that required ECLS were as follows: (1)
39 patients with usual postoperative LCOS that was unresponsive to inotro-
pic drugs or intra-aortic balloon pumping (IABP), (2) 21 patients with
witnessed cardiac arrest that was unresponsive to standard advancedrdiovascular Surgery c Volume 147, Number 1 283
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Dcardiopulmonary life support, and (3) 33 patients with postoperative car-
diopulmonary bypass (CPB) weaning failure. The study was approved by
the institutional ethics committee/review board of the University of Ulsan,
and the requirement for informed patient consent was waived in view of the
retrospective nature of the study.
ECLS Devices
In all 93 patients, venoarterial ECLSwas administeredvia peripheral can-
nulation involving the common femoral artery and vein or internal jugular
vein. TheECLSsystemconsisted of a centrifugal pump, a hollow-fibermem-
brane oxygenator with an integral heat exchanger, and a heparin-bound cir-
cuit. Three types of ECLS system were used: the Capiox emergency bypass
system (Terumo, Tokyo, Japan)was used for 80 (86%) patients, the PLS sys-
tem (Maquet, Hirrlingen, Germany) for 6 (6.5%), and the Bio-Console 560
system (Medtronic, Minneapolis, MN) for 7 (7.5%) patients.
Anticoagulation
Before cannulation, an intravenous heparin bolus of 100 U/kg was ad-
ministered to achieve a celite activated clotting time (ACT) (measured us-
ing a Hemochron 401 machine; Soma Technology, Bloomfield, Conn) of
300 seconds, except in patients with a high risk of bleeding or in patients
who were actively bleeding. The latter 2 classes of patients received
a half dose of heparin. After the patients were connected to the ECLS cir-
cuit, the ACT was normally maintained within a range of 180 to 200 sec-
onds. However, when hemorrhage had occurred or was anticipated, an
attempt was made to ensure a lower ACT of 160 to 180 seconds. During
the weaning process, an ACTof less than 200 seconds was achieved by sig-
nificantly reducing the pump flow rate.Whenever CPBweaning failed after
surgery, ECLS was performed. Heparin was then replaced by protamine
sulfate, which was administered at a dose 25% lower than normally used.
In 2010, we began to use nafamostat mesilate (Futhan; Torii Pharmaceu-
tical, Tokyo, Japan), a synthetic serine protease inhibitor, as an alternative
anticoagulant to heparin for actively bleeding patients immediately after
surgery. For these patients, a half dose of heparin was administered before
cannulation, and ACTwas maintained within 160 to 180 seconds after the
administration of a starting dose of 0.75 mg/kg nafamostat mesilate. The
maintenance dose of nafamostat mesilate was adjusted between 0.5 mg/
kg and 1 mg/kg according to hourly measurements of ACT.
ECLS Management
The ECLS blood flow was maintained at a cardiac index of at least 2.4
L $min1 $m2. The mean arterial blood pressure was targeted at 60 to 70
mm Hg. To maintain the appropriate mean arterial pressure, we adminis-
tered vasopressors as needed, rather than inotropic agents. The patients’ he-
matocrit values were maintained at 30% to 35%, and platelets were
transfused when the platelet count was less than 100 3 103/mm3 for
high bleeding risk patients and 503 103/mm3 otherwise. An antegrade per-
fusion catheter was routinely placed distal to the arterial cannulation site284 The Journal of Thoracic and Cardiovascular Surgfor distal limb perfusion, except in instances in which this placement failed
owing to technical difficulties. If signs of ischemia in the distal limbs de-
veloped, we changed the arterial cannulation to the opposite side of the
femoral artery.
Successful weaning was defined as the separation from ECLS without
mortality over a 24-hour period without resumption of ECLS.9 Generally,
the weaning process started with the prospect of the recovery of cardiac
function when echocardiography showed adequate ventricular filling and
an ejection fraction of greater than 30% to 35% at ECLS flow of a cardiac
index of 1.0 L $min1 $m2. As ECLSweaning proceeded, the ECLS flow
was gradually reduced to 0.5 L/min. If the hemodynamic parameters re-
main stable for 30 minutes at the ECLS flow of 0.5 L/min, ECLS was re-
moved from the bedside.
Statistical Analysis
Categorical variables are presented as frequencies and percentages and
were compared using the c2 test or Fisher’s exact test. Continuous variables
are expressed as mean  standard deviation and were compared using the
Student unpaired t test. Formultivariable analyses of mortality data, a logis-
tic regressionmodel was used. Variables with a P value .20 in univariable
analyses were candidates for the multivariable models. Multivariable anal-
yses involved a backward elimination technique, and only variables with
a P value  .10 were used in the final model. Results were expressed as
a hazard ratio (HR) with 95% confidence intervals (CIs). The predictive
value of pre-ECLS lactate level for mortality was evaluated by analyzing
areas under receiver operating characteristic curves, with their 95% CIs.
The optimal cutoff value corresponded to the value with the greatest accu-
racy. All reported P values are 2-sided. Statistical analyses were performed
with SPSS 18.0 for Windows Software (SPSS Inc, Chicago, Ill).RESULTS
The baseline characteristics of the patients are listed in
Table 1. The patients who died were older and required
a longer CPB time during surgery than those who survived.
The preoperative echocardiographic data, however, showed
no significant differences between the 2 groups.
Table 2 compares the variables related to ECLS manage-
ment and complications in patients according to their final
vital status. The levels of serum lactate level before ECLS
were significantly higher in patients who died than in those
in the group of survivors. Twenty-one (22.6%) patients
were supported with an IABP before ECLS was begun.
For 33 (35.4%) patients, ECLS commenced in the operat-
ing room, immediately after the main cardiac procedure,
and as a result of CPB weaning failure. For the remaining
60 patients, ECLS commenced in the intensive care unit
owing to delayed circulatory collapse after cardiac surgery.
Among these 60 patients, 21 patients had cardiac arrest
while ECLS was being instituted, and the median arrest
time before the initiation of ECLS was 31 minutes (range,
3-142 minutes). Including these 21 patients, the median
time interval from the end of the operation to the initiation
of ECLS in the intensive care unit was 13.5 hours (range,
0.6-702.1 hours).Overall Outcomes
Details of complications that arose during ECLS are pro-
vided in Table 2. Twenty-five (26.9%) patients requiredery c January 2014
TABLE 1. Baseline characteristics of the patients who underwent
ECLS after major cardiac surgery
Variables
Total
(n ¼ 93)
Survived
(n ¼ 23)
Died
(n ¼ 70) P
Age, y 60.6  13.8 54.2  16.7 62.7  12.2 .033
Male gender (%) 46 (49.5) 13 (56.5) 33 (47.1) .48
Body surface area, m2 1.65  0.2 1.64  0.18 1.66  0.20 .64
Hypertension (%) 41 (44.1) 9 (39.1) 32 (45.7) .64
Diabetes mellitus (%) 17 (18.3) 5 (21.7) 12 (17.1) .76
Echocardiographic
data
LV end-systolic
dimension, mm
38.0  12.7 42.8  15.5 36.3  11.3 .083
LV end-diastolic
dimension, mm
54.4  10.4 57.7  11.8 53.2  9.8 .12
LV ejection fraction 52.4  15.6 47.5  18.3 54.1  14.3 .13
LV mass, g 200.9  80.9 202.1  69.5 200.5  85.0 .93
Operation type .11
Valve surgery (%) 28 (30.1) 8 (34.8) 20 (28.6)
CABG (%) 21 (22.6) 6 (26.1) 15 (21.4)
Valve þ CABG (%) 12 (16.1) 1 (4.3) 11 (15.7)
Aorta surgery (%) 5 (5.4) 0 (0) 5 (7.1)
Aorta þ valve or
CABG (%)
14 (15.1) 2 (8.7) 12 (17.1)
Others (%) 13 (14.0) 6 (26.1) 7 (10)
Previous cardiac
surgery (%)
9 (9.7) 1 (4.3) 8 (11.4) .44
ACC time, min 132.2  76.8 130.9  52.2 132.5  83.3 .93
CPB time, min 215.0  152.6 177.6  78.3 262.9  149.0 .014
Values are n (%) or mean  standard deviation. ECLS, Extracorporeal life support;
LV, left ventricle; CABG, coronary arterial bypass grafting; ACC, aorta crossclamp;
CPB, cardiopulmonary bypass.
TABLE 2. ECLS data for patients who did and did not survive
Variables
Total
(n ¼ 93)
Survived
(n ¼ 23)
Died
(n ¼ 70) P
Clinical situation of
ECLS implantation
At the end of
operation (%)
33 (35.4) 5 (21.7) 28 (40) .14
Arrest (%) 21 (22.6) 4 (17.4) 17 (24.3) .58
Interval from operation
finish to ECLS, h
13.5 15.6 (3-51) 10.6 (0.6-702) .067
Blood pH level before
initiating ECLS
7.31  0.11 7.33  0.11 7.31  0.11 .54
Blood lactate level
before initiating
ECLS, mmol/L
9.06  4.59 6.55  3.81 10.24  4.49 .001
Duration of ECLS, h 71 66.9 (0.8-460) 75.8 (0.5-517) .20
Using nafamostat
anticoagulant (%)
14 (15.1) 6 (26.0) 8 (11.4) .19
Complications
during ECLS
Mediastinal
bleeding (%)
36 (37.6) 5 (21.7) 21 (42.9) .085
Reoperation
for bleeding
25 5 20
Massive bleeding
(not operated)
10 0 11
Dialysis (%) 57 (61.3) 12 (52.2) 45 (64.3) .33
Neurologic
events (%)
7 (7.5) 1 (4.3) 6 (8.6) .17
Lower limb
ischemia (%)
14 (15.0) 3 (13.0) 11 (15.7) .76
Bowel ischemia (%) 6 (6.5) 0 (0) 6 (8.6) .19
Cannulation-related
complications (%)
10 (10.8) 3 (13.0) 7 (10) .70
Values are n (%) mean standard deviation or median (range). ECLS, Extracorporeal
life support.
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Dreoperation owing to mediastinal bleeding, and 11 (11.8%)
died of uncontrolled bleeding immediately after the opera-
tion, while on ECLS. Among 14 (15.1%) patients who
had complications associated with distal limb ischemia, 2
underwent toe amputation. New-onset neurologic events
occurred in 7 (7.5%) patients, including intracerebral hem-
orrhage in 3, subdural hemorrhage in 1, cerebral infarction
in 2, and spinal infarct resulting in quadriplegia in 1 further
patient. Six (6.5%) patients had complications that in-
volved bowel infarction and all died of multiple organ fail-
ure, including 2 patients who underwent bowel resection.
Figure 1 summarizes the outcomes of ECLS. One patient
underwent a successful HT and survived. The successful
weaning rate was 41.9% (39/93). Fifteen patients died after
successful weaning from ECLS in hospital. Of these 15 pa-
tients, 5 had multiple organ failure, 2 had profound cardiac
failure, 2 had sepsis, 2 had panperitonitis, 2 had aortic rup-
ture, 1 had intracerebral hemorrhage, and 1 had gastrointes-
tinal bleeding. Hence, 24 patients survived until the time
they were discharged. During follow-up, 1 patient died of
sepsis owing to graft infection after an ascending aorta re-
placement 182 days after the operation. Another patient
died of heart failure 742 days after coronary artery bypassThe Journal of Thoracic and Cagrafting. A final total of 23 (24.3%) patients, including 1
HT recipient, survived until the end of the follow-up period
(median follow-up duration, 611 days; range, 125-2,247
days).
The outcomes of ECLS were summarized according to 3
clinical situations in Figure 2. Notably, the results of the
CPB weaning failure group were poor, showing a weaning
rate of 21.2% and a survival of 15.1%. In contrast, success-
ful weaning and survivals were 53.3% and 40.0%, respec-
tively, in patients with other clinical setting requiring
ECLS.
Both the successful weaning and survivals tended to im-
prove over the course of 7 years of experience (Figure 3).
Independent Predictors of Mortality
Multivariable analyses revealed that old age (HR, 1.04;
95% CI, 1.01-1.06; P¼ .001), a high serum lactate level be-
fore ECLS initiation (HR, 1.13; 95% CI, 1.06-1.20;
P< .001), CPB weaning failure after surgery (HR, 3.22;rdiovascular Surgery c Volume 147, Number 1 285
FIGURE 1. Flow chart of the outcomes in patients having extracorporeal
life support (ECLS).
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D95% CI, 1.79-5.78; P<.001), and postoperative bleeding
(HR, 2.00; 95% CI, 1.17-3.42; P ¼ .012) were independent
factors associated with mortality. In contrast, the administra-
tion of the anticoagulant nafamostat mesilate (HR, 0.47;
95% CI, 0.23-0.97; P ¼ .040) was found to be associated
with an improved outcome of ECLS. The independent pre-
dictors for weaning failure from ECLS were also summa-
rized in Table 3.
The predictive value of the serum lactate level before ini-
tiation of ECLS for mortality was assessed using the re-
ceiver operating characteristic curve. The best accuracyFIGURE 2. Outcomes of extracorporeal life support (ECLS) according to 3 diff
output syndrome.
286 The Journal of Thoracic and Cardiovascular Surgfor prediction of mortality was at the cutoff value of 7.9
mmol/L, with a sensitivity of 63% and a specificity of
68%, showing an area under the curve of 0.73 (95% CI,
0.61-0.84; P ¼ .002) (Figure 4). The patients whose serum
lactate level was below the cutoff value of 7.9 mmol/L be-
fore the initiation of ECLS showed higher survivals than the
patients whose serum lactate level was greater than 7.9
mmol/L (Figure 5).DISCUSSION
Notwithstanding improvements in surgical techniques,
cardiac anesthesia, and myocardial protection during major
cardiac surgery over the past few decades, the incidence of
LCOS that requires mechanical support has not de-
creased.10 This can be attributed to the extended indications
of surgical candidates, many of whom are older and have
impaired ventricular function and comorbidities.
ECLS is a widely accepted temporary mechanical sup-
port and is used as ‘‘rescue therapy’’ for emergency and un-
expected cardiogenic shock owing to the ease and rapidity
with which it can be applied and its ability to rapidly restore
the circulation that supports biventricular and respiratory
function. Nonetheless, ECLS is strongly associated with
complications such as bleeding, limb ischemia, infection,
and thromboembolic events,11 and the occurrence of these
events appears to increase throughout the course of
ECLS. Hence, when the failing heart is unlikely to recover
after more than 48 to 72 hours of ECLS, it is advisable to
bridge this procedure to either implantation of a VAD or
HT before end-organ insults or complications arise.2,7
Owing to the costs associated with implantable VADs,
HT is currently the only solution to treat profound hearterent clinical situations.CPB,Cardiopulmonary bypass; LCOS, low cardiac
ery c January 2014
FIGURE 3. Both the successful weaning rate and survival appear to have
increases over the course of 7 years of experience (P<.001).
FIGURE 4. Receiver operating characteristic curve for the predictive
value of serum lactate level for mortality. AUC, Area under the curve;
CI, confidence interval.
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tients waiting for heart transplants is many times greater
than the supply of donor hearts, and fewer than 100 heart
transplants are performed annually despite the recent in-
crease in rates of organ donation.8 Hence, the primary inten-
tion of ECLS should be limited to improving cardiac
recovery in patients with LCOS after cardiac surgery.
The successful weaning rate from ECLS was measured at
41.9% in the present study. However, given that 38.4% of
the patients in our study cohort died in the hospital after suc-
cessful weaning, the hospital survival was only 25.8%. This
outcome is comparable with the results of previous studies
of ECLS that reported early survival rates ranging from
16% to 41%.2-5,12 These reports also suggested that
there has not been significant improvement in early
survival over the past few decades, despite technical
improvements in ECLS devices and better management
skills. Similarly, a previous analysis of 517 patients who
received ECLS has reported a relatively constant survival
over the course of a 12-year period.3 In contrast, the survival
after ECLS at our center appears to have increased over theTABLE 3. Multivariable risk factors analyses for weaning failure and
mortality
Variables
Weaning failure Mortality
HR 95% CI P HR 95% CI P
Age 1.03 1.00-1.07 .089 1.04 1.01-1.06 .001*
High serum lactate
level before ECLS
1.14 1.01-1.28 .028* 1.13 1.06-1.20 <.001*
CPB weaning failure
after surgery
6.50 2.03-20.79 .002* 3.22 1.79-5.78 <.001*
Using nafamostat
anticoagulant
0.33 0.09-1.23 .099 0.47 0.23-0.97 .04*
ECLS, Extracorporeal life support; CPB, cardiopulmonary bypass; HR, hazard ratio;
CI, confidence interval. *P<.05.
The Journal of Thoracic and Capast 7 years of the study period, with a rate of 40% for the
past 2 years (Figure 2). A reduction in the frequency of
bleeding complications, which is associated with the use
of nafamostat mesilate for anticoagulation, may account
for this better outcome. The low lactate levels in our patients
before the initiation of ECLS also likely contributed to the
result.
Recent studies have demonstrated that older age, evi-
dence of organ system dysfunction, a history of cardiac
surgery, extensive aortic operations, neurologic events,
and failure to use an IABP are all predictors of mortality
during ECLS.3,4,13 Our current findings, however, suggest
that advanced age, high levels of serum lactate before
ECLS initiation, CPB weaning failure at the end of
the operation, postoperative bleeding, and nonuse ofFIGURE 5. Kaplan-Meier analysis revealing differences in mortality ac-
cording to the serum lactate (Lac) level before the initiation of extracorpo-
real life support.
rdiovascular Surgery c Volume 147, Number 1 287
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during ECLS.
The discrepancies in the results between this study and
the cited studies may be attributed to the differences in the
subject patient population and discrepancies in analytic
viewpoints. New-onset neurologic events, for instance, oc-
curred in 7 patients during ECLS in the present study, and
most of these patients died (n ¼ 6, 85.7%). Although the
neurologic events were strongly related to resultant mor-
tality, we believe the causal relationship between the neu-
rologic events and mortality is difficult to be proven in
a limited number of patients. This particularly matters be-
cause the neurologic damage may be one of the conse-
quences in the process of irreversible multiple organ
damage rather than an independent risk factor of mortality.
For these reasons, we did not include the neurologic
events as one of the candidate risk covariates when deter-
mining the risk factors of mortality in this study. The con-
comitant usage of IABP during ECLS was believed to
provide superior coronary perfusion potentially leading
to more favorable outcomes.3,4,13 In the present study,
however, there were no significant differences in overall
clinical outcomes between the IABP group and the non-
IABP group. Regarding this issue, we may find a clue
from a recently published study that prospectively ran-
domized patients to IABP support versus no IABP support
in the setting of acute myocardial infarction presenting
with shock.14 The study found no additional benefit
from IABP in these patients. We believe that the sufficient
coronary perfusion pressure can be achieved by maintain-
ing mean arterial blood pressure over 60 mm Hg even
without IABP in the setting of ECMO support. Moreover,
IABP may carry further risks of complications related to
vascular access. Risk versus benefit of additional IABP
in the setting of ECMO support may need further verifica-
tions through prospective studies.
The early initiation of ECLS before the onset of profound
cardiopulmonary collapse and secondary organ injuries is
ideal. Outcomes of ECLS were significantly associated
with the severity of pre-ECLS cardiogenic shock, as mea-
sured by lactate levels.3,15 Our data also suggest that high
lactate levels are associated with adverse outcomes. We
routinely measured the serum lactate level every 2 to 3
hours, and the value just before the initiation of ECLS
was analyzed to determine the timing appropriate for the
initiation of ECLS. Previous studies of ECLS after
postcardiotomy cardiogenic shock indicated that
postoperative mediastinal bleeding was the major problem
in the management of this treatment.3,12,16 To reduce
bleeding complications, we maintained blood cell
components and coagulation factors at adequate levels
and routinely administered aprotinin or tranxeamic acid.
Despite these efforts, the redo thoracotomy rate for288 The Journal of Thoracic and Cardiovascular Surgthe correction of excessive bleeding ranged from
40.0% to 87.3%.
In 2010, we began to administer nafamostat mesilate (Fu-
than; Torii Pharmaceutical, Tokyo, Japan) to the ECLS reg-
imen for patients with a tendency to bleed excessively.
Nafamostat mesilate is a synthetic protease inhibitor that in-
hibits coagulation and fibrinolysis owing to its potent inhib-
itory activity toward thrombin, plasmin, trypsin, kallikrein,
certain coagulation factors (XIIa, Xa), and certain comple-
ment factors (C1r, C1s).17,18 The use of nafamostat mesilate
has been associated with fewer hemorrhagic complications
than heparin during extracorporeal circulation during
continuous venovenous hemodiafiltration.19 A favorable
outcome from the use of nafamostat mesilate as an antico-
agulant during ECLS was also reported previously.20 Ab-
normal bleeding after CPB may be the result of excessive
fibrinolysis21,22 and/or a transient impairment of platelet
function.23,24 Murase and colleagues25 have demonstrated
that nafamostat mesilate inhibits fibrinolysis and preserves
both platelet counts and platelet function during CPB and
the postoperative course, and it contributes to the reduction
of blood loss postoperatively. On the other hand, heparin en-
hances fibrinolytic activity during CPB, leading to the dis-
solution of clots and recurrence of bleeding. Fourteen
patients in our present study cohort who received nafamo-
stat mesilate for anticoagulation instead of heparin showed
a lower occurrence of bleeding complication than patients
who received heparin. Of these 14 patients, only 4 (28%)
had mediastinal bleeding, compared with 32 (40.5%) of
the 79 patients who received heparin and had mediastinal
bleeding. However, the difference in frequencies of bleed-
ing complications between the 2 groups was not statistically
significant. This may be due to the small number of patients
in the nafamostat mesilate group and the fact that the hepa-
rin group includes patients without a risk of bleeding com-
plications, whereas the nafamostat mesilate group only
contains patients at high risk of bleeding complications.
The adequacy of ACT determinations to evaluate the need
to monitor the extent of anticoagulation mediated by nafa-
mostat mesilate remains to be established.
Limitations
This study is subject to the limitations inherent in retro-
spective studies of observational data from a single center.
The nonrandomized design might have affected our results
owing to unmeasured confounders, procedure bias, or de-
tection bias. The study was conducted in the setting of
a high-volume tertiary referral center in a country with
unique medicosocial circumstances where availability of
VAD or HT is very limited, and therefore the results may
not be generalizable to other centers in different situations.
Although the subject patient number was not small com-
pared with previous studies of ECLS, the absolute numberery c January 2014
Park et al Acquired Cardiovascular Diseaseof patients enrolled was small, particularly the number of
patients who received nafamostat mesilate.CONCLUSIONS
Owing to the lack of availability of implantable VAD and
limited availability of donor hearts, ECLS has been in-
tended to bridge to cardiac recovery. High lactate levels be-
fore ECLS and susceptibility to bleeding complications are
independent predictors of mortality after ECLS. Hence,
ECLS should be initiated before development of profound
lactic acidosis. Moreover, nafamostat mesilate should be
considered as an alternative to heparin to reduce the risk
of bleeding-related complications in patients at high risk
of this occurrence.A
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